Genomic Instability and Cancer: Mechanisms and Therapeutic Implications

Diego Fernandez^*
*Correspondence: Diego Fernandez, Department of Immunology and Oncology, Centro Nacional de Biotecnología, Madrid, Spain, Email:

Keywords

Genomic instability • Cancer • DNA damage • Replication errors • DNA repair • Therapeutic implications

Introduction

Cancer is a complex and heterogeneous disease characterized by uncontrolled cell growth and proliferation. While the molecular mechanisms driving cancer development are multifaceted, genomic instability emerges as a central player in tumorigenesis and tumor evolution. Genomic instability encompasses a wide range of alterations in the genome, including DNA damage, replication errors, chromosomal abnormalities and mutations [1]. These alterations disrupt the integrity of the genome, leading to the accumulation of genetic alterations that drive cancer initiation, progression and therapeutic resistance.

Genomic instability is a pervasive feature of cancer, contributing to the initiation, progression and therapeutic resistance of malignant tumors. Characterized by increased rates of DNA damage, mutations and chromosomal aberrations, genomic instability fuels the evolutionary trajectory of cancer cells, enabling the acquisition of hallmark phenotypes such as sustained proliferative signaling, evasion of growth suppressors, resistance to cell death and replicative immortality. While cancer is a heterogeneous disease with diverse etiological factors and genetic drivers, genomic instability represents a common denominator underlying the complexity and adaptability of malignant tumors.

The maintenance of genomic stability is orchestrated by a myriad of DNA repair pathways, cell cycle checkpoints and surveillance mechanisms that safeguard the integrity of the genome. However, perturbations in these regulatory networks can unleash a cascade of genomic alterations, culminating in the dysregulation of critical cellular processes and the emergence of malignant phenotypes [2]. In this mini-review, we will explore the molecular mechanisms underlying genomic instability in cancer, highlighting the diverse pathways and processes implicated in driving tumor evolution and heterogeneity. Furthermore, we will discuss the therapeutic implications of targeting genomic instability for cancer treatment, focusing on emerging strategies aimed at exploiting vulnerabilities conferred by the genomic chaos of malignant cells.

Literature Review

Genomic instability arises from a variety of endogenous and exogenous factors that perturb the normal functioning of the genome. Endogenous sources of genomic instability include errors in DNA replication, defects in DNA repair mechanisms and aberrant cell cycle regulation. Replication errors can result in nucleotide mismatches, insertion-deletion mutations and replication slippage, leading to genomic alterations. Meanwhile, impaired DNA repair pathways, such as mismatch repair (MMR) and homologous recombination (HR), compromise the cell's ability to maintain genomic integrity, predisposing cells to the accumulation of DNA damage. Exogenous factors, such as radiation, chemical carcinogens and viral infections, can also induce DNA damage and genomic instability by generating DNA lesions, oxidative stress and chromosomal rearrangements [3].

Genomic instability plays a critical role in cancer development, progression and therapeutic response. It fuels the acquisition of genetic alterations that drive oncogenesis by promoting the inactivation of tumor suppressor genes and the activation of oncogenes. Moreover, genomic instability contributes to intratumor heterogeneity, fostering the emergence of subclones with distinct phenotypic traits and therapeutic vulnerabilities. The dynamic interplay between genomic instability and tumor evolution underlies the emergence of therapy-resistant clones, posing a significant challenge for cancer treatment [4]. Furthermore, genomic instability is associated with poor clinical outcomes, including tumor aggressiveness, metastasis and recurrence, highlighting its prognostic significance in cancer.

Discussion

Exploiting the vulnerabilities conferred by genomic instability holds promise for developing novel cancer therapies. Targeting DNA repair pathways represents a rational strategy for selectively killing cancer cells while sparing normal cells. Inhibitors of DNA repair enzymes, such as poly(ADP-ribose) polymerase (PARP) inhibitors and DNA-dependent protein kinase (DNAPK) inhibitors, have shown efficacy in tumors with defects in homologous recombination repair, such as those harboring BRCA mutations [5,6]. Additionally, agents that induce DNA damage, such as ionizing radiation and chemotherapy, capitalize on the heightened sensitivity of genomically unstable cancer cells to DNA-damaging agents. Furthermore, immunotherapies, such as immune checkpoint inhibitors, exploit the immunogenicity of tumors with high mutational burdens resulting from genomic instability.

Conclusion

Genomic instability is a hallmark of cancer that drives tumorigenesis, tumor evolution and therapeutic resistance. Understanding the mechanisms underlying genomic instability is crucial for developing effective cancer therapies. Targeting genomic instability pathways represents a promising approach for selectively killing cancer cells while sparing normal cells. Continued research into the molecular mechanisms of genomic instability and the development of targeted therapies hold promise for improving cancer outcomes and overcoming therapeutic resistance.

Acknowledgement

None.

Conflict of Interest

None.

References

1. van den Boogaard, Winnie MC, Daphne SJ Komninos and Wilbert P. Vermeij. "Chemotherapy side-effects: not all DNA damage is equal."Cancers14 (2022): 627.

   Google Scholar, Crossref, Indexed at

2. Wang, Faliang, Kiran Vij, Lin Li and Paarth Dodhiawala, et al. "Phospho-Ser784-VCP Drives Resistance of Pancreatic Ductal Adenocarcinoma to Genotoxic Chemotherapies and Predicts the Chemo-Sensitizing Effect of VCP Inhibitor."Cancers13 (2021): 5076.

   Google Scholar, Crossref, Indexed at

3. Técher, Hervé, Stéphane Koundrioukoff, Alain Nicolas and Michelle Debatisse. "The impact of replication stress on replication dynamics and DNA damage in vertebrate cells."Nat Rev Genet18 (2017): 535-550.

   Google Scholar, Crossref, Indexed at

4. Meng, Xiangbing, Jason Z. Gao, Sean Michael T. Gomendoza and John W. Li, et al. "Recent advances of WEE1 inhibitors and statins in cancers with p53 mutations."Front Med 8 (2021): 737951.

   Google Scholar, Crossref, Indexed at

5. Kim, Hoon, Nam-Phuong Nguyen, Kristen Turner and Sihan Wu, et al. "Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers."Nat Genet 52 (2020): 891-897.

   Google Scholar, Crossref, Indexed at

6. Garza-Rodríguez, María Lourdes, Mariel Araceli Oyervides-Muñoz and Antonio Alí Pérez-Maya, et al. "Analysis of HPV integrations in Mexican pre-tumoral cervical lesions reveal centromere-enriched breakpoints and abundant unspecific HPV regions." Int J Mol Sci 22 (2021): 3242.

   Google Scholar, Crossref, Indexed at